Ben Sasse Says 'Miracle Drug' Shrank Pancreatic Cancer Tumors, Caused Bloody Face

Key Points:

• Former U.S. Senator Ben Sasse, diagnosed with terminal Stage 4 pancreatic cancer in December 2025, credits "providence, prayer and a miracle drug" for his survival beyond initial prognosis of four months.
• Sasse's tumor volume has shrunk by 76% after taking daraxonrasib, an experimental targeted oral therapy that inhibits RAS gene mutations common in over 90% of pancreatic cancers; the drug is still in clinical trials but has shown promising results in extending median survival.
• Daraxonrasib, developed by Revolution Medicines and granted FDA Breakthrough Therapy Designation, has demonstrated a median survival of about 13 months in metastatic pancreatic cancer patients compared to under seven months with chemotherapy, though it can cause significant side effects like bleeding skin rashes.
• Despite the progress, Sasse acknowledges his cancer remains terminal, expressing gratitude for the perspective it has given him and lamenting the limited time he expects to have with his family, including his wife and three children.
• Pancreatic cancer remains one of the deadliest cancers due to its hidden growth and resistance to treatment, with a five-year survival rate of just 3% for metastatic cases, underscoring the critical need for new therapies like daraxonrasib.